Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 8. Отображено 7.
06-01-2022 дата публикации

Meloxicam co-crystals

Номер: US20220002283A1
Автор: Ramakoteswara Rao Jetti, Srinivas Enugula, Subramanyam Dandala, Sureshbabu JAYACHANDRA, Venkata Naga Vikas Chandra Dev RAVI, Vijaya Krishna RAVI
Принадлежит: MYLAN LABORATORIES LTD

Co-crystals of meloxicam co-formers can be prepared by co-crystallization from a polar solvent, such as aqueous dimethyl sulfoxide; or by slurry processes, such as with ethyl acetate. Such co-crystals have improved purities and are physically stable under storage for several months.

Подробнее
Номер записи: 1
04-04-2019 дата публикации

POLYMORPHIC FORMS OF SOFOSBUVIR

Номер: US20190100550A1
Автор: Dev Ravi Venkata Haga Vikas Chandra, INDUKURI Anjaneyaraju, Jetti Ramakoteswara Rao, Mande Hemant Malhari, Pilli Narasimha Murty, Ravi Vijaya Krishna
Принадлежит: MYLAN LABORATORIES LIMITED

The present disclosure provides novel crystalline sofosbuvir form-M3 and a process for the preparation of sofosbuvir form-M3. The crystalline sofosbuvir form-M3 disclosed herein may be useful in the formulation of pharmaceutical dosage forms. 1. Crystalline sofosbuvir form-M3.2. The crystalline sofosbuvir form-M3 of claim 1 , characterized by a PXRD pattern having peaks at 2θ angle positions of 7.61 claim 1 , 16.92 claim 1 , and 20.47±0.2°.3. The crystalline sofosbuvir form-M3 of claim 1 , characterized by a PXRD pattern having peaks at 2θ angle positions of 7.61 claim 1 , 14.19 claim 1 , 16.92 claim 1 , 17.98 claim 1 , 19.58 claim 1 , 20.47 claim 1 , and 23.27±0.2°.4. The crystalline sofosbuvir form-M3 of claim 1 , characterized by a PXRD pattern as shown in .5. A process for the preparation of crystalline sofosbuvir form-M3 claim 1 , comprising the steps of:a. dissolving sofosbuvir in a solvent to form a solution;b. adding an anti-solvent to the solution; andc. isolating crystalline sofosbuvir form-M3.6. The process according to claim 5 , wherein the solvent comprises a water-miscible solvent.7. The process according to claim 6 , wherein the solvent further comprises water.8. The process according to claim 6 , wherein the water-miscible solvent is selected from the group consisting of methanol claim 6 , ethanol claim 6 , isopropanol claim 6 , 1-butanol claim 6 , isobutanol claim 6 , 1-pentanol claim 6 , acetone claim 6 , acetonitrile claim 6 , N claim 6 ,N-dimethylformamide claim 6 , dimethylsulfoxide claim 6 , 1 claim 6 ,2-dimethoxyethane claim 6 , and mixtures thereof.9. The process according to claim 5 , wherein the anti-solvent is water.10. The process according to claim 5 , further comprising the step of stirring after adding anti-solvent and before the isolating step.11. The process according to claim 5 , wherein the solution is seeded with crystalline sofosbuvir form-M3 after adding an anti-solvent and before the isolating step.12. (canceled)13. (canceled) ...

Подробнее
Номер записи: 2
01-11-2018 дата публикации

Process for the Preparation of Sofosbuvir

Номер: US20180312484A1
Автор: DANDALA Subramanyam, Dev Vikas Chandra, Jayachandra Sureshbabu, KAUSHIK Vipin Kumar, Kottolla Saiprasad, Muggu Chaitanya, Rao Potla Venkata Srinivasa, Ravi Vijaya Krishna, VAKITI Srinivas
Принадлежит: MYLAN LABORATORIES LIMITED

A process for the preparation of intermediates 9, useful in the synthesis of sofosbuvir, as well as intermediates of formula [12] are disclosed herein. 2. The process according to claim 1 , wherein the step of converting the compound of formula 17 to the compound of formula 16 is performed in the presence of a thionyl chloride and a base.3. The process according to claim 2 , wherein the base is selected from the group consisting of alkali metal hydroxides claim 2 , alkali metal carbonates claim 2 , amine bases claim 2 , alcoholic amine bases claim 2 , and mixtures thereof.4. The process according to claim 1 , wherein the oxidizing agent is selected from the group consisting of sodium hypochlorite claim 1 , peroxides claim 1 , and mixtures thereof.5. The process according to claim 1 , wherein the compound of formula 17 may be directly converted to the compound of formula 15 by reacting the compound of formula 17 with a sulfonating agent in the presence of a base.6. The process according to claim 5 , wherein the sulfonating agent selected from the group consisting of sulfuryl chloride claim 5 , sulfuryl fluoride claim 5 , and mixtures thereof;7. The process according to wherein the base is selected from the group consisting of alkali metal hydroxides claim 5 , alkali metal carbonates claim 5 , amine bases claim 5 , alcoholic amine bases and mixtures thereof.8. The process according to claim 1 , wherein the step of fluorinating the compound of formula 15 to the compound of formula 14 is performed in the presence of a fluorinating agent.9. The process according to claim 7 , wherein the fluorinating agent is selected from the group consisting of hydrogen fluoride claim 7 , tetraethylammonium fluoride claim 7 , tetrabutylammonium fluoride claim 7 , and mixtures thereof.10. The process according to claim 1 , wherein the hydrolyzing of formula 14 is carried out in the presence of an acid.11. The process according to claim 9 , wherein the acid is selected from the group ...

Подробнее
Номер записи: 3
11-08-2020 дата публикации

Polymorphic forms of sofosbuvir

Номер: US10738071B2
Автор: Anjaneyaraju Indukuri, Hemant Malhari MANDE, Narasimha Murty Pilli, Ramakoteswara Rao Jetti, RAVI Venkata Naga Vikas Chandra Dev, Vijaya Krishna RAVI
Принадлежит: MYLAN LABORATORIES LTD

The present disclosure provides novel crystalline sofosbuvir form-M3 and a process for the preparation of sofosbuvir form-M3. The crystalline sofosbuvir form-M3 disclosed herein may be useful in the formulation of pharmaceutical dosage forms.

Подробнее
Номер записи: 4
15-09-2021 дата публикации

Meloxicam co-crystals

Номер: EP3877385A1
Автор: Ramakoteswara Rao Jetti, Srinivas Enugula, Subramanyam Dandala, Sureshbabu JAYACHANDRA, Venkata Naga Vikas Chandra Dev RAVI, Vijaya Krishna RAVI
Принадлежит: MYLAN LABORATORIES LTD

Co-crystals of meloxicam co-formers can be prepared by co-crystallization from a polar solvent, such as aqueous dimethyl sulfoxide; or by slurry processes, such as with ethyl acetate. Such co-crystals have improved purities and are physically stable under storage for several months.

Подробнее
Номер записи: 5
14-05-2020 дата публикации

Meloxicam co-crystals

Номер: WO2020095316A1
Автор: Ramakoteswara Rao Jetti, Srinivas Enugula, Subramanyam Dandala, Sureshbabu JAYACHANDRA, Venkata Naga Vikas Chandra Dev RAVI, Vijaya Krishna RAVI
Принадлежит: MYLAN LABORATORIES LIMITED

Co-crystals of meloxicam co-formers can be prepared by co-crystallization from a polar solvent, such as aqueous dimethyl sulfoxide; or by slurry processes, such as with ethyl acetate. Such co-crystals have improved purities and are physically stable under storage for several months.

Подробнее
Номер записи: 6
12-08-2010 дата публикации

Crystalline form of 2-chloro-3-[4-(4-chlorophenyl) cyclohexyl] [1,4]naphthoquinone, process for the same and use for producing 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4] naphthoquinone

Номер: WO2010023686A3
Автор: Debashish Data, Hemraj Lande, Jitendra Sharma, Mounishwarachar Virupakshachar Agadi, Saswata Lahiri, Sreedhar Rapolu, Venkata Naga Vikas Chandra Dev RAVI
Принадлежит: Matrix Laboratories Limited

Disclosed herein discloses a crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone and process for preparing the same and use thereof. The present invention also provides a process for producing 2-[4-(4- chlorophenyl)cyclohexyl] -3 -hydroxy- 1,4- naphthoquinone employing the crystalline form of 2-Chloro-3-[4-(4-chlorophenyl) cyclohexyl] [l,4]naphthoquinone to obtain pure and better yield.

Подробнее
Номер записи: 7